Wolfe Research Downgrades Corcept Therapeutics to Underperform, Announces $50 Price Target
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsDowngradesPrice Target
Wolfe Research analyst Kalpit Patel downgrades Corcept Therapeutics (NASDAQ:CORT) from Peer Perform to Underperform and announces $50 price target.
Wolfe Research analyst Kalpit Patel downgrades Corcept Therapeutics (NASDAQ:CORT) from Peer Perform to Underperform and announces $50 price target.